Oura, the Finnish company behind the Oura Ring health-tracking device, kicked off its US initial public offering roadshow on 21 September 2026, seeking a fully diluted valuation of about $15.62 billion ahead of a planned Nasdaq listing under the ticker OURA.
Raising up to $2.2 billion
Oura filed to list on 3 September and is offering 13.5 million of its own shares, with existing stockholders offering a further 36.5 million, at an indicated price range of $40 to $44 a share. At the top of that range, the sale would raise as much as $2.2 billion. Goldman Sachs, Morgan Stanley and J.P. Morgan are leading the offering as underwriters, with first trades expected the week of 28 September. The targeted valuation marks a sharp rise from the roughly $11 billion Oura reached in a late-stage private funding round the previous year.
From fitness ring to health data company
Oura’s ring tracks sleep, heart rate, temperature and activity, competing with wrist-worn devices from larger technology companies while positioning itself around longer-term health and readiness data rather than step counts alone. The IPO would make it one of the highest-profile wearable technology listings in recent years, testing investor appetite for consumer health hardware paired with a subscription software model.
The company has built much of its growth on pairing the ring hardware with an ongoing subscription for personalised health insights, a model that gives it recurring revenue beyond the initial device sale and is a large part of what underpins its jump in valuation over the past year.
Why It Matters
A successful listing at this valuation would signal that investors see lasting value in continuous personal health data collected outside a clinical setting, not just in the ring itself. For a category that has often struggled to justify premium pricing beyond an initial novelty purchase, Oura’s IPO will be closely watched as a test of whether wearable health tracking has matured into a durable business.
Leave a Reply